$NKTX
Nkarta, Inc.

2024 Q1 Form 10-K Financial Statement

#000095017024034735 Filed on March 21, 2024

View on sec.gov

Income Statement

Concept 2024 Q1 2023 Q4 2023
Revenue $0.00 $0.00 $0.00
YoY Change
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin $7.525M $7.863M $34.88M
YoY Change -7.98% -3.39% 24.3%
% of Gross Profit
Research & Development $25.24M $23.32M $96.77M
YoY Change -3.44% -13.12% 6.46%
% of Gross Profit
Depreciation & Amortization $2.300M $2.251M $5.869M
YoY Change 187.5% 208.78% 125.73%
% of Gross Profit
Operating Expenses $32.76M $31.19M $131.7M
YoY Change -4.52% -10.86% 10.67%
Operating Profit -$32.76M -$131.7M
YoY Change -4.52% 10.67%
Interest Expense $3.246M $3.456M $14.11M
YoY Change -6.32% 19.58% 152.45%
% of Operating Profit
Other Income/Expense, Net $3.244M -$25.00K $42.00K
YoY Change -7.26% -94.89% -99.18%
Pretax Income -$29.52M -$27.75M -$117.5M
YoY Change -4.21% -14.82% 3.22%
Income Tax $0.00 $0.00
% Of Pretax Income
Net Earnings -$29.52M -$27.75M -$117.5M
YoY Change -4.21% -14.82% 3.22%
Net Earnings / Revenue
Basic Earnings Per Share -$0.58 -$2.40
Diluted Earnings Per Share -$0.58 -$0.57 -$2.40
COMMON SHARES
Basic Shares Outstanding 49.42M 49.07M 49.01M
Diluted Shares Outstanding 50.68M 49.01M

Balance Sheet

Concept 2024 Q1 2023 Q4 2023
SHORT-TERM ASSETS
Cash & Short-Term Investments $437.4M $248.2M $248.2M
YoY Change 35.27% -29.52% -29.52%
Cash & Equivalents $250.3M $31.04M $31.04M
Short-Term Investments $187.1M $217.1M $217.1M
Other Short-Term Assets $5.387M $4.882M $4.882M
YoY Change 59.76% 66.68% -42.87%
Inventory
Prepaid Expenses $3.263M
Receivables
Other Receivables
Total Short-Term Assets $442.8M $253.1M $253.1M
YoY Change 33.29% -29.84% -29.84%
LONG-TERM ASSETS
Property, Plant & Equipment $78.52M $119.3M $119.3M
YoY Change 12.53% 92.66% 10.79%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments $9.814M
YoY Change 63.13%
Other Assets $3.719M $6.539M $6.539M
YoY Change 98.88% 253.46% 42.37%
Total Long-Term Assets $134.2M $125.8M $125.8M
YoY Change 6.49% 12.08% 12.08%
TOTAL ASSETS
Total Short-Term Assets $442.8M $253.1M $253.1M
Total Long-Term Assets $134.2M $125.8M $125.8M
Total Assets $576.9M $378.9M $378.9M
YoY Change 25.92% -19.89% -19.89%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $3.177M $3.665M $3.665M
YoY Change -41.29% 108.12% 108.12%
Accrued Expenses $12.93M $18.81M $18.81M
YoY Change -12.71% 17.3% -3.18%
Deferred Revenue
YoY Change
Short-Term Debt $0.00 $0.00 $0.00
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities $22.19M $23.33M $23.33M
YoY Change -14.6% 5.82% 5.82%
LONG-TERM LIABILITIES
Long-Term Debt $0.00 $0.00 $0.00
YoY Change
Other Long-Term Liabilities $81.10M $82.27M $82.27M
YoY Change -5.2% 4.56% 4.56%
Total Long-Term Liabilities $81.10M $82.27M $82.27M
YoY Change -5.2% 4.56% 4.56%
TOTAL LIABILITIES
Total Short-Term Liabilities $22.19M $23.33M $23.33M
Total Long-Term Liabilities $81.10M $82.27M $82.27M
Total Liabilities $103.3M $105.6M $105.6M
YoY Change -7.39% 4.83% 4.83%
SHAREHOLDERS EQUITY
Retained Earnings -$465.0M -$435.4M
YoY Change 33.35% 36.96%
Common Stock $938.7M $708.7M
YoY Change 34.96% 2.59%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity $473.7M $273.3M $273.3M
YoY Change
Total Liabilities & Shareholders Equity $576.9M $378.9M $378.9M
YoY Change 25.92% -19.89% -19.89%

Cashflow Statement

Concept 2024 Q1 2023 Q4 2023
OPERATING ACTIVITIES
Net Income -$29.52M -$27.75M -$117.5M
YoY Change -4.21% -14.82% 3.22%
Depreciation, Depletion And Amortization $2.300M $2.251M $5.869M
YoY Change 187.5% 208.78% 125.73%
Cash From Operating Activities -$28.51M -$23.35M -$86.16M
YoY Change 37.33% 218.56% 51.16%
INVESTING ACTIVITIES
Capital Expenditures $175.0K $6.807M $28.15M
YoY Change -96.37% -80.57% -40.25%
Acquisitions
YoY Change
Other Investing Activities $21.66M $22.64M $107.2M
YoY Change -48.12% -43.08% -177.89%
Cash From Investing Activities $21.49M $15.84M $79.02M
YoY Change -41.82% 233.62% -142.78%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net $691.0K
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities 226.3M 295.0K 691.0K
YoY Change 22626500.0% -30.42% -99.68%
NET CHANGE
Cash From Operating Activities -28.51M -23.35M -86.16M
Cash From Investing Activities 21.49M 15.84M 79.02M
Cash From Financing Activities 226.3M 295.0K 691.0K
Net Change In Cash 219.2M -7.222M -6.454M
YoY Change 1255.71% 234.35% -71.54%
FREE CASH FLOW
Cash From Operating Activities -$28.51M -$23.35M -$86.16M
Capital Expenditures $175.0K $6.807M $28.15M
Free Cash Flow -$28.68M -$30.16M -$114.3M
YoY Change 12.12% -28.81% 9.79%

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
CY2023 dei Entity Central Index Key
EntityCentralIndexKey
0001787400
CY2023 dei Amendment Flag
AmendmentFlag
false
CY2023 dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
FY
CY2023Q4 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2022Q4 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2023Q4 us-gaap Preferred Stock Value
PreferredStockValue
CY2022Q4 us-gaap Preferred Stock Value
PreferredStockValue
CY2023 dei Document Type
DocumentType
10-K
CY2023 dei Document Annual Report
DocumentAnnualReport
true
CY2023 dei Document Period End Date
DocumentPeriodEndDate
2023-12-31
CY2023 dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--12-31
CY2023 dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2023
CY2023 dei Document Transition Report
DocumentTransitionReport
false
CY2023 dei Entity File Number
EntityFileNumber
001-39370
CY2023 dei Entity Registrant Name
EntityRegistrantName
Nkarta, Inc.
CY2023 dei Entity Incorporation State Country Code
EntityIncorporationStateCountryCode
DE
CY2023 dei Entity Tax Identification Number
EntityTaxIdentificationNumber
47-4515206
CY2023 dei Entity Address Address Line1
EntityAddressAddressLine1
1150 Veterans Boulevard
CY2023 dei Entity Address City Or Town
EntityAddressCityOrTown
South San Francisco
CY2023 dei Entity Address State Or Province
EntityAddressStateOrProvince
CA
CY2023 dei Entity Address Postal Zip Code
EntityAddressPostalZipCode
94080
CY2023 dei City Area Code
CityAreaCode
925
CY2023 dei Local Phone Number
LocalPhoneNumber
407-1049
CY2023 dei Security12b Title
Security12bTitle
Common Stock, $0.0001 par value per share
CY2023 dei Trading Symbol
TradingSymbol
NKTX
CY2023 dei Security Exchange Name
SecurityExchangeName
NASDAQ
CY2023 dei Entity Well Known Seasoned Issuer
EntityWellKnownSeasonedIssuer
No
CY2023 dei Entity Voluntary Filers
EntityVoluntaryFilers
No
CY2023 dei Entity Current Reporting Status
EntityCurrentReportingStatus
Yes
CY2023 dei Entity Interactive Data Current
EntityInteractiveDataCurrent
Yes
CY2023 dei Entity Filer Category
EntityFilerCategory
Non-accelerated Filer
CY2023 dei Entity Small Business
EntitySmallBusiness
true
CY2023 dei Entity Emerging Growth Company
EntityEmergingGrowthCompany
true
CY2023 dei Entity Ex Transition Period
EntityExTransitionPeriod
true
CY2023 dei Icfr Auditor Attestation Flag
IcfrAuditorAttestationFlag
false
CY2023 dei Document Fin Stmt Error Correction Flag
DocumentFinStmtErrorCorrectionFlag
false
CY2023 dei Entity Shell Company
EntityShellCompany
false
CY2023Q2 dei Entity Public Float
EntityPublicFloat
38400000
CY2024Q1 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
49416186
CY2023 dei Auditor Firm
AuditorFirmId
42
CY2023 dei Auditor Name
AuditorName
Ernst & Young LLP
CY2023 dei Auditor Location
AuditorLocation
California
CY2023Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
31040000
CY2022Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
37494000
CY2023Q4 us-gaap Short Term Investments
ShortTermInvestments
217149000
CY2022Q4 us-gaap Short Term Investments
ShortTermInvestments
314649000
CY2023Q4 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
4882000
CY2022Q4 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
8545000
CY2023Q4 us-gaap Assets Current
AssetsCurrent
253071000
CY2022Q4 us-gaap Assets Current
AssetsCurrent
360688000
CY2023Q4 us-gaap Restricted Cash Noncurrent
RestrictedCashNoncurrent
2743000
CY2022Q4 us-gaap Restricted Cash Noncurrent
RestrictedCashNoncurrent
2743000
CY2023Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
79326000
CY2022Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
61908000
CY2023Q4 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
39949000
CY2022Q4 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
45749000
CY2023Q4 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
3796000
CY2022Q4 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
1850000
CY2023Q4 us-gaap Assets
Assets
378885000
CY2022Q4 us-gaap Assets
Assets
472938000
CY2023Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
3665000
CY2022Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
1761000
CY2023Q4 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
6069000
CY2022Q4 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
4249000
CY2023Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
13596000
CY2022Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
16036000
CY2023Q4 us-gaap Liabilities Current
LiabilitiesCurrent
23330000
CY2022Q4 us-gaap Liabilities Current
LiabilitiesCurrent
22046000
CY2023Q4 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
82270000
CY2022Q4 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
78685000
CY2023Q4 us-gaap Liabilities
Liabilities
105600000
CY2022Q4 us-gaap Liabilities
Liabilities
100731000
CY2023Q4 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.0001
CY2022Q4 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.0001
CY2023Q4 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
54350179
CY2022Q4 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
54350179
CY2023Q4 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0
CY2023Q4 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0
CY2022Q4 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0
CY2022Q4 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0
CY2023Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.0001
CY2022Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.0001
CY2023Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
100000000
CY2022Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
100000000
CY2023Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
49181295
CY2023Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
49181295
CY2022Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
48877806
CY2022Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
48877806
CY2023Q4 us-gaap Common Stock Value
CommonStockValue
5000
CY2022Q4 us-gaap Common Stock Value
CommonStockValue
5000
CY2023Q4 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
708706000
CY2022Q4 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
690814000
CY2023Q4 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
8000
CY2022Q4 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
-679000
CY2023Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-435434000
CY2022Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-317933000
CY2023Q4 us-gaap Stockholders Equity
StockholdersEquity
273285000
CY2022Q4 us-gaap Stockholders Equity
StockholdersEquity
372207000
CY2023Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
378885000
CY2022Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
472938000
CY2023 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
96773000
CY2022 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
90897000
CY2023 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
34877000
CY2022 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
28058000
CY2023 us-gaap Operating Expenses
OperatingExpenses
131650000
CY2022 us-gaap Operating Expenses
OperatingExpenses
118955000
CY2023 us-gaap Operating Income Loss
OperatingIncomeLoss
-131650000
CY2022 us-gaap Operating Income Loss
OperatingIncomeLoss
-118955000
CY2023 us-gaap Investment Income Net
InvestmentIncomeNet
14107000
CY2022 us-gaap Investment Income Net
InvestmentIncomeNet
5588000
CY2023 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
42000
CY2022 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
-470000
CY2023 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
14149000
CY2022 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
5118000
CY2023 us-gaap Net Income Loss
NetIncomeLoss
-117501000
CY2022 us-gaap Net Income Loss
NetIncomeLoss
-113837000
CY2023 us-gaap Net Income Loss
NetIncomeLoss
-117501000
CY2022 us-gaap Net Income Loss
NetIncomeLoss
-113837000
CY2023 us-gaap Unrealized Gain Loss On Investments
UnrealizedGainLossOnInvestments
687000
CY2022 us-gaap Unrealized Gain Loss On Investments
UnrealizedGainLossOnInvestments
-529000
CY2023 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-116814000
CY2022 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-114366000
CY2023 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-2.4
CY2023 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-2.4
CY2022 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-2.61
CY2022 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-2.61
CY2023 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
49014300
CY2023 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
49014300
CY2022 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
43631722
CY2022 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
43631722
CY2021Q4 us-gaap Stockholders Equity
StockholdersEquity
250967000
CY2022 nktx Stock Issued During Period Value Vesting Of Shares Of Common Stock Subject To Repurchase
StockIssuedDuringPeriodValueVestingOfSharesOfCommonStockSubjectToRepurchase
15000
CY2022 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
1397000
CY2022 us-gaap Stock Issued During Period Value Employee Stock Purchase Plan
StockIssuedDuringPeriodValueEmployeeStockPurchasePlan
445000
CY2022 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
16856000
CY2022 us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
-529000
CY2022 us-gaap Net Income Loss
NetIncomeLoss
-113837000
CY2022Q4 us-gaap Stockholders Equity
StockholdersEquity
372207000
CY2023 nktx Stock Issued During Period Value Vesting Of Shares Of Common Stock Subject To Repurchase
StockIssuedDuringPeriodValueVestingOfSharesOfCommonStockSubjectToRepurchase
2000
CY2023 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
161000
CY2023 us-gaap Stock Issued During Period Value Employee Stock Purchase Plan
StockIssuedDuringPeriodValueEmployeeStockPurchasePlan
530000
CY2023 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
17199000
CY2023 us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
687000
CY2023 us-gaap Net Income Loss
NetIncomeLoss
-117501000
CY2023Q4 us-gaap Stockholders Equity
StockholdersEquity
273285000
CY2023 us-gaap Profit Loss
ProfitLoss
-117501000
CY2022 us-gaap Profit Loss
ProfitLoss
-113837000
CY2023 us-gaap Share Based Compensation
ShareBasedCompensation
17199000
CY2022 us-gaap Share Based Compensation
ShareBasedCompensation
16856000
CY2023 us-gaap Depreciation And Amortization
DepreciationAndAmortization
5869000
CY2022 us-gaap Depreciation And Amortization
DepreciationAndAmortization
2637000
CY2023 us-gaap Accretion Amortization Of Discounts And Premiums Investments
AccretionAmortizationOfDiscountsAndPremiumsInvestments
8940000
CY2022 us-gaap Accretion Amortization Of Discounts And Premiums Investments
AccretionAmortizationOfDiscountsAndPremiumsInvestments
818000
CY2023 us-gaap Operating Lease Right Of Use Asset Amortization Expense
OperatingLeaseRightOfUseAssetAmortizationExpense
2222000
CY2022 us-gaap Operating Lease Right Of Use Asset Amortization Expense
OperatingLeaseRightOfUseAssetAmortizationExpense
3935000
CY2023 us-gaap Debt Securities Available For Sale Realized Gain Loss
DebtSecuritiesAvailableForSaleRealizedGainLoss
34000
CY2022 us-gaap Debt Securities Available For Sale Realized Gain Loss
DebtSecuritiesAvailableForSaleRealizedGainLoss
-490000
CY2023 us-gaap Operating Lease Impairment Loss
OperatingLeaseImpairmentLoss
4100000
CY2023 us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
-1716000
CY2022 us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
1489000
CY2023 us-gaap Increase Decrease In Operating Lease Liability
IncreaseDecreaseInOperatingLeaseLiability
4986000
CY2022 us-gaap Increase Decrease In Operating Lease Liability
IncreaseDecreaseInOperatingLeaseLiability
32469000
CY2023 nktx Increase Decrease In Accounts Payable And Accrued And Other Liabilities
IncreaseDecreaseInAccountsPayableAndAccruedAndOtherLiabilities
4223000
CY2022 nktx Increase Decrease In Accounts Payable And Accrued And Other Liabilities
IncreaseDecreaseInAccountsPayableAndAccruedAndOtherLiabilities
2757000
CY2023 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-86160000
CY2022 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-57000000
CY2023 us-gaap Payments To Acquire Investments
PaymentsToAcquireInvestments
260233000
CY2022 us-gaap Payments To Acquire Investments
PaymentsToAcquireInvestments
385887000
CY2023 us-gaap Proceeds From Sale Maturity And Collections Of Investments
ProceedsFromSaleMaturityAndCollectionsOfInvestments
367395000
CY2022 us-gaap Proceeds From Sale Maturity And Collections Of Investments
ProceedsFromSaleMaturityAndCollectionsOfInvestments
248309000
CY2023 us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
28147000
CY2022 us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
47111000
CY2023 us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
79015000
CY2022 us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-184689000
CY2022 nktx Proceeds From Secondary Offering Net Of Issuance Costs
ProceedsFromSecondaryOfferingNetOfIssuanceCosts
215611000
CY2022 nktx Proceeds From At The Market Offering Net Of Issuance Costs
ProceedsFromAtTheMarketOfferingNetOfIssuanceCosts
1559000
CY2023 us-gaap Proceeds From Stock Plans
ProceedsFromStockPlans
530000
CY2022 us-gaap Proceeds From Stock Plans
ProceedsFromStockPlans
445000
CY2023 us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
161000
CY2022 us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
1397000
CY2023 us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
691000
CY2022 us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
219012000
CY2023 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
-6454000
CY2022 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
-22677000
CY2022Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
40237000
CY2021Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
62914000
CY2023Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
33783000
CY2022Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
40237000
CY2023Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
31040000
CY2022Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
37494000
CY2023Q4 us-gaap Restricted Cash
RestrictedCash
2743000
CY2022Q4 us-gaap Restricted Cash
RestrictedCash
2743000
CY2023Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
33783000
CY2022Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
40237000
CY2023 nktx Noncash Or Part Noncash Acquisition Fixed Assets Acquired Recorded In Accounts Payable And Accrued And Other Current Liabilities
NoncashOrPartNoncashAcquisitionFixedAssetsAcquiredRecordedInAccountsPayableAndAccruedAndOtherCurrentLiabilities
268000
CY2022 nktx Noncash Or Part Noncash Acquisition Fixed Assets Acquired Recorded In Accounts Payable And Accrued And Other Current Liabilities
NoncashOrPartNoncashAcquisitionFixedAssetsAcquiredRecordedInAccountsPayableAndAccruedAndOtherCurrentLiabilities
4579000
CY2023 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
49014300
CY2023Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-435400000
CY2023Q4 nktx Cash Cash Equivalents Restricted Cash And Short Term Investments
CashCashEquivalentsRestrictedCashAndShortTermInvestments
250900000
CY2023 us-gaap Use Of Estimates
UseOfEstimates
<p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Use of Estimates</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The preparation of financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the amounts reported in the Company’s financial statements and accompanying notes. On an ongoing basis, management evaluates its estimates, including those related to preclinical studies and clinical trial accruals, fair value of assets and liabilities, impairment of assets, leases, share-based compensation and income taxes. Management bases its estimates on historical experience, knowledge of current events and actions it may undertake in the future that management believes to be reasonable under the circumstances. Actual results may differ from these estimates and assumptions.</span></p>
CY2023 us-gaap Concentration Risk Credit Risk
ConcentrationRiskCreditRisk
<p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Concentration of Credit Risk</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Financial </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">instruments, which potentially subject the Company to concentration of credit risk, consist primarily of cash, cash equivalents and investments. The Company maintains cash, cash equivalents and investments with various high credit quality and are invested through banks and other financial institutions in the United States. Such deposits may be in excess of federally insured limits. Management believes that the Company is not exposed to</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">significant </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">credit risk due to the financial position of the depository institutions in which those deposits are held. The Company has not experienced any losses on deposits since inception.</span></p>
CY2022Q4 us-gaap Loss Contingency Accrual At Carrying Value
LossContingencyAccrualAtCarryingValue
0
CY2023Q4 us-gaap Loss Contingency Accrual At Carrying Value
LossContingencyAccrualAtCarryingValue
0
CY2023 nktx Employee Stock Purchase Plan Look Back Period
EmployeeStockPurchasePlanLookBackPeriod
P6M
CY2023 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
49014300
CY2022 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
43631722
CY2023 us-gaap Number Of Operating Segments
NumberOfOperatingSegments
1
us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
0
CY2023 us-gaap Net Income Loss
NetIncomeLoss
-117501000
CY2022 us-gaap Net Income Loss
NetIncomeLoss
-113837000
CY2023 us-gaap Weighted Average Number Of Shares Issued Basic
WeightedAverageNumberOfSharesIssuedBasic
49014357
CY2022 us-gaap Weighted Average Number Of Shares Issued Basic
WeightedAverageNumberOfSharesIssuedBasic
43635044
CY2023 nktx Weighted Average Number Of Shares Unvested Common Stock Issued Upon Early Exercise Of Common Stock Options
WeightedAverageNumberOfSharesUnvestedCommonStockIssuedUponEarlyExerciseOfCommonStockOptions
-57
CY2022 nktx Weighted Average Number Of Shares Unvested Common Stock Issued Upon Early Exercise Of Common Stock Options
WeightedAverageNumberOfSharesUnvestedCommonStockIssuedUponEarlyExerciseOfCommonStockOptions
-3322
CY2022 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
43631722
CY2023 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-2.4
CY2023 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-2.4
CY2022 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-2.61
CY2022 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-2.61
CY2023 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
7311294
CY2022 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
5876511
CY2023Q4 us-gaap Money Market Funds At Carrying Value
MoneyMarketFundsAtCarryingValue
30751000
CY2023Q4 us-gaap Short Term Investments
ShortTermInvestments
217149000
CY2023Q4 us-gaap Assets Fair Value Disclosure
AssetsFairValueDisclosure
247900000
CY2022Q4 us-gaap Money Market Funds At Carrying Value
MoneyMarketFundsAtCarryingValue
36494000
CY2022Q4 us-gaap Short Term Investments
ShortTermInvestments
314649000
CY2022Q4 us-gaap Assets Fair Value Disclosure
AssetsFairValueDisclosure
351143000
CY2023Q4 us-gaap Available For Sale Debt Securities Amortized Cost Basis
AvailableForSaleDebtSecuritiesAmortizedCostBasis
217141000
CY2023Q4 us-gaap Available For Sale Debt Securities Accumulated Gross Unrealized Loss Before Tax
AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
69000
CY2023Q4 us-gaap Available For Sale Debt Securities Accumulated Gross Unrealized Gain Before Tax
AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
77000
CY2023Q4 us-gaap Available For Sale Securities Debt Securities
AvailableForSaleSecuritiesDebtSecurities
217149000
CY2022Q4 us-gaap Available For Sale Debt Securities Amortized Cost Basis
AvailableForSaleDebtSecuritiesAmortizedCostBasis
315328000
CY2022Q4 us-gaap Available For Sale Debt Securities Accumulated Gross Unrealized Loss Before Tax
AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
762000
CY2022Q4 us-gaap Available For Sale Debt Securities Accumulated Gross Unrealized Gain Before Tax
AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
83000
CY2022Q4 us-gaap Available For Sale Securities Debt Securities
AvailableForSaleSecuritiesDebtSecurities
314649000
CY2022Q4 us-gaap Availableforsale Securities Sold At Par
AvailableforsaleSecuritiesSoldAtPar
27000000
CY2022Q4 us-gaap Debt Securities Available For Sale Realized Loss
DebtSecuritiesAvailableForSaleRealizedLoss
200000
CY2023Q1 us-gaap Availableforsale Securities Sold At Par
AvailableforsaleSecuritiesSoldAtPar
67600000
CY2023Q1 us-gaap Debt Securities Available For Sale Realized Loss
DebtSecuritiesAvailableForSaleRealizedLoss
300000
CY2022 nktx Impairments
Impairments
300000
CY2023Q4 us-gaap Prepaid Expense Current
PrepaidExpenseCurrent
3263000
CY2022Q4 us-gaap Prepaid Expense Current
PrepaidExpenseCurrent
5616000
CY2023Q4 us-gaap Other Assets Current
OtherAssetsCurrent
1619000
CY2022Q4 us-gaap Other Assets Current
OtherAssetsCurrent
2929000
CY2023Q4 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
4882000
CY2022Q4 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
8545000
CY2023Q4 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
91019000
CY2022Q4 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
67732000
CY2023Q4 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
11693000
CY2022Q4 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
5824000
CY2023Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
79326000
CY2022Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
61908000
CY2023 us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
5900000
CY2022 us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
2600000
CY2023Q4 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
6722000
CY2022Q4 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
6691000
CY2023Q4 nktx Accrued Research And Development Costs Current
AccruedResearchAndDevelopmentCostsCurrent
5845000
CY2022Q4 nktx Accrued Research And Development Costs Current
AccruedResearchAndDevelopmentCostsCurrent
3486000
CY2023Q4 nktx Accrued Property And Equipment Liabilities Current
AccruedPropertyAndEquipmentLiabilitiesCurrent
174000
CY2022Q4 nktx Accrued Property And Equipment Liabilities Current
AccruedPropertyAndEquipmentLiabilitiesCurrent
5001000
CY2023Q4 us-gaap Accounts Payable And Other Accrued Liabilities Current
AccountsPayableAndOtherAccruedLiabilitiesCurrent
855000
CY2022Q4 us-gaap Accounts Payable And Other Accrued Liabilities Current
AccountsPayableAndOtherAccruedLiabilitiesCurrent
858000
CY2023Q4 us-gaap Accounts Payable And Accrued Liabilities Current
AccountsPayableAndAccruedLiabilitiesCurrent
13596000
CY2022Q4 us-gaap Accounts Payable And Accrued Liabilities Current
AccountsPayableAndAccruedLiabilitiesCurrent
16036000
CY2022 us-gaap Operating Lease Cost
OperatingLeaseCost
11220000
CY2023 us-gaap Variable Lease Cost
VariableLeaseCost
1018000
CY2022 us-gaap Variable Lease Cost
VariableLeaseCost
462000
CY2023 us-gaap Operating Lease Cost
OperatingLeaseCost
10900000
CY2023 us-gaap Short Term Lease Cost
ShortTermLeaseCost
18000
CY2022 us-gaap Short Term Lease Cost
ShortTermLeaseCost
45000
CY2023 us-gaap Lease Cost
LeaseCost
11936000
CY2022 us-gaap Lease Cost
LeaseCost
11727000
CY2023 us-gaap Operating Lease Payments
OperatingLeasePayments
11540000
CY2022 us-gaap Operating Lease Payments
OperatingLeasePayments
6887000
CY2023Q4 us-gaap Operating Lease Weighted Average Discount Rate Percent
OperatingLeaseWeightedAverageDiscountRatePercent
0.098
CY2023 nktx Right Of Use Assets Obtained In Exchange For Operating Lease Liabilities Resulting From New Leases
RightOfUseAssetsObtainedInExchangeForOperatingLeaseLiabilitiesResultingFromNewLeases
0
CY2023 nktx Right Of Use Assets Obtained In Exchange For Operating Lease Liabilities Resulting From Modifications Of Existing Leases
RightOfUseAssetsObtainedInExchangeForOperatingLeaseLiabilitiesResultingFromModificationsOfExistingLeases
400000
CY2023Q4 us-gaap Lessee Operating Lease Liability Payments Due Next Twelve Months
LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths
12818000
CY2023Q4 us-gaap Lessee Operating Lease Liability Payments Due Year Two
LesseeOperatingLeaseLiabilityPaymentsDueYearTwo
13027000
CY2023Q4 us-gaap Lessee Operating Lease Liability Payments Due Year Three
LesseeOperatingLeaseLiabilityPaymentsDueYearThree
13462000
CY2023Q4 us-gaap Lessee Operating Lease Liability Payments Due Year Four
LesseeOperatingLeaseLiabilityPaymentsDueYearFour
13912000
CY2023Q4 us-gaap Lessee Operating Lease Liability Payments Due Year Five
LesseeOperatingLeaseLiabilityPaymentsDueYearFive
14378000
CY2023Q4 us-gaap Lessee Operating Lease Liability Payments Due After Year Five
LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive
72876000
CY2023Q4 us-gaap Lessee Operating Lease Liability Payments Due
LesseeOperatingLeaseLiabilityPaymentsDue
140473000
CY2023Q4 us-gaap Lessee Operating Lease Liability Undiscounted Excess Amount
LesseeOperatingLeaseLiabilityUndiscountedExcessAmount
52134000
CY2023Q4 us-gaap Operating Lease Liability
OperatingLeaseLiability
88339000
CY2023Q4 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
6069000
CY2023Q4 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
82270000
CY2023Q4 us-gaap Operating Lease Liability
OperatingLeaseLiability
88339000
CY2021Q3 us-gaap Lessee Operating Lease Term Of Contract
LesseeOperatingLeaseTermOfContract
P12Y
CY2021Q3 nktx Cash Received For Tenant Improvement Allowances To Be Repaid
CashReceivedForTenantImprovementAllowancesToBeRepaid
4400000
CY2023Q2 nktx Cash Received For Tenant Improvement Allowances To Be Repaid
CashReceivedForTenantImprovementAllowancesToBeRepaid
4400000
CY2023Q4 us-gaap Lessee Operating Lease Discount Rate
LesseeOperatingLeaseDiscountRate
0.08
CY2023 us-gaap Operating Lease Impairment Loss
OperatingLeaseImpairmentLoss
4100000
CY2023Q4 us-gaap Guarantee Obligations Current Carrying Value
GuaranteeObligationsCurrentCarryingValue
0
CY2022Q4 us-gaap Guarantee Obligations Current Carrying Value
GuaranteeObligationsCurrentCarryingValue
0
CY2020Q3 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
100000000
CY2020Q3 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.0001
CY2020Q3 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
54350179
CY2020Q3 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.0001
CY2023 nktx Schedule Of Share Based Compensation Additional Information Related To Stock Options
ScheduleOfShareBasedCompensationAdditionalInformationRelatedToStockOptions
<p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Additional information related to the Company’s stock options is summarized below (in thousands, except per share amounts):</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p> <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;"> <tr style="visibility:collapse;"> <td style="width:64.553%;"></td> <td style="width:1.56%;"></td> <td style="width:1%;"></td> <td style="width:14.163%;"></td> <td style="width:1%;"></td> <td style="width:1.56%;"></td> <td style="width:1%;"></td> <td style="width:14.163%;"></td> <td style="width:1%;"></td> </tr> <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;text-align:left;"> <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td colspan="6" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Year Ended December 31,</span></p></td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> </tr> <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;text-align:left;"> <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">2023</span></p></td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">2022</span></p></td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> </tr> <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Weighted-average grant-date fair value of stock option grants per share</span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">3.36</span></p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;"> </span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">8.60</span></p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;"> </span></p></td> </tr> <tr style="height:10pt;background-color:#ffffff;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Intrinsic value of options exercised</span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">39</span></p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;"> </span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">4,268</span></p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;"> </span></p></td> </tr> </table>
CY2023 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
3.36
CY2022 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
8.6
CY2023 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercises In Period Total Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue
39000
CY2022 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercises In Period Total Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue
4268000
CY2023Q4 us-gaap Common Stock Capital Shares Reserved For Future Issuance
CommonStockCapitalSharesReservedForFutureIssuance
11171592
CY2023 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
17199000
CY2022 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
16856000
CY2023Q4 us-gaap Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized
EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized
19500000
CY2023 us-gaap Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Period For Recognition1
EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1
P2Y7M6D
CY2023 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Expiration Period
SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod
P10Y
CY2023 us-gaap Dividends Share Based Compensation
DividendsShareBasedCompensation
0
CY2023 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Payments
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendPayments
0
CY2023 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
0
CY2023 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
0
CY2022 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
0
CY2023Q4 nktx Deferred Tax Liabilities Depreciation And Amortization
DeferredTaxLiabilitiesDepreciationAndAmortization
7851000
CY2022Q4 nktx Deferred Tax Liabilities Depreciation And Amortization
DeferredTaxLiabilitiesDepreciationAndAmortization
958000
CY2023Q4 us-gaap Deferred Tax Assets Liabilities Net
DeferredTaxAssetsLiabilitiesNet
0
CY2023 us-gaap Income Tax Reconciliation Income Tax Expense Benefit At Federal Statutory Income Tax Rate
IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate
-24675000
CY2022 us-gaap Income Tax Reconciliation Income Tax Expense Benefit At Federal Statutory Income Tax Rate
IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate
-23906000
CY2023 us-gaap Income Tax Reconciliation State And Local Income Taxes
IncomeTaxReconciliationStateAndLocalIncomeTaxes
-1438000
CY2022 us-gaap Income Tax Reconciliation State And Local Income Taxes
IncomeTaxReconciliationStateAndLocalIncomeTaxes
-1566000
CY2023 nktx Income Tax Reconciliation Permanent Items
IncomeTaxReconciliationPermanentItems
1656000
CY2022 nktx Income Tax Reconciliation Permanent Items
IncomeTaxReconciliationPermanentItems
1891000
CY2023 us-gaap Income Tax Reconciliation Tax Credits Research
IncomeTaxReconciliationTaxCreditsResearch
6170000
CY2022 us-gaap Income Tax Reconciliation Tax Credits Research
IncomeTaxReconciliationTaxCreditsResearch
3426000
CY2023 us-gaap Income Tax Reconciliation Change In Deferred Tax Assets Valuation Allowance
IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance
30627000
CY2022 us-gaap Income Tax Reconciliation Change In Deferred Tax Assets Valuation Allowance
IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance
27007000
CY2023 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
0
CY2022 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
0
CY2023Q4 us-gaap Deferred Tax Assets Operating Loss Carryforwards
DeferredTaxAssetsOperatingLossCarryforwards
43491000
CY2022Q4 us-gaap Deferred Tax Assets Operating Loss Carryforwards
DeferredTaxAssetsOperatingLossCarryforwards
36732000
CY2023Q4 nktx Deferred Tax Assets Depreciation And Amortization
DeferredTaxAssetsDepreciationAndAmortization
334000
CY2022Q4 nktx Deferred Tax Assets Depreciation And Amortization
DeferredTaxAssetsDepreciationAndAmortization
316000
CY2023Q4 us-gaap Deferred Tax Assets Tax Credit Carryforwards Research
DeferredTaxAssetsTaxCreditCarryforwardsResearch
19782000
CY2022Q4 us-gaap Deferred Tax Assets Tax Credit Carryforwards Research
DeferredTaxAssetsTaxCreditCarryforwardsResearch
11999000
CY2023Q4 us-gaap Deferred Tax Assets Tax Deferred Expense Compensation And Benefits Share Based Compensation Cost
DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost
4668000
CY2022Q4 us-gaap Deferred Tax Assets Tax Deferred Expense Compensation And Benefits Share Based Compensation Cost
DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost
3552000
CY2023Q4 us-gaap Deferred Tax Assets Tax Deferred Expense Reserves And Accruals Accrued Liabilities
DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities
1402000
CY2022Q4 us-gaap Deferred Tax Assets Tax Deferred Expense Reserves And Accruals Accrued Liabilities
DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities
1367000
CY2023Q4 nktx Deferred Tax Assets Lease Liability
DeferredTaxAssetsLeaseLiability
18551000
CY2022Q4 nktx Deferred Tax Assets Lease Liability
DeferredTaxAssetsLeaseLiability
19062000
CY2023Q4 us-gaap Deferred Tax Assets Other
DeferredTaxAssetsOther
49000
CY2022Q4 us-gaap Deferred Tax Assets Other
DeferredTaxAssetsOther
35000
CY2023Q4 nktx Deferred Tax Assets Section One Seventy Four Capitalized Research And Development
DeferredTaxAssetsSectionOneSeventyFourCapitalizedResearchAndDevelopment
30147000
CY2022Q4 nktx Deferred Tax Assets Section One Seventy Four Capitalized Research And Development
DeferredTaxAssetsSectionOneSeventyFourCapitalizedResearchAndDevelopment
17352000
CY2023Q4 us-gaap Deferred Tax Assets Gross
DeferredTaxAssetsGross
118424000
CY2022Q4 us-gaap Deferred Tax Assets Gross
DeferredTaxAssetsGross
90415000
CY2023Q4 us-gaap Deferred Tax Assets Valuation Allowance
DeferredTaxAssetsValuationAllowance
102169000
CY2022Q4 us-gaap Deferred Tax Assets Valuation Allowance
DeferredTaxAssetsValuationAllowance
71368000
CY2023Q4 us-gaap Deferred Tax Assets Net
DeferredTaxAssetsNet
16255000
CY2022Q4 us-gaap Deferred Tax Assets Net
DeferredTaxAssetsNet
19047000
CY2023Q4 nktx Deferred Tax Liabilities Right Of Use Asset
DeferredTaxLiabilitiesRightOfUseAsset
8404000
CY2022Q4 nktx Deferred Tax Liabilities Right Of Use Asset
DeferredTaxLiabilitiesRightOfUseAsset
18089000
CY2022Q4 us-gaap Deferred Tax Assets Liabilities Net
DeferredTaxAssetsLiabilitiesNet
0
CY2023 us-gaap Valuation Allowance Deferred Tax Asset Change In Amount
ValuationAllowanceDeferredTaxAssetChangeInAmount
30600000
CY2022 us-gaap Valuation Allowance Deferred Tax Asset Change In Amount
ValuationAllowanceDeferredTaxAssetChangeInAmount
27000000
CY2023Q4 us-gaap Unrecognized Tax Benefits
UnrecognizedTaxBenefits
3700000
CY2022Q4 us-gaap Unrecognized Tax Benefits
UnrecognizedTaxBenefits
2300000
CY2023 us-gaap Unrecognized Tax Benefits Income Tax Penalties And Interest Expense
UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense
0
CY2022 us-gaap Unrecognized Tax Benefits Income Tax Penalties And Interest Expense
UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense
0
CY2022Q4 us-gaap Unrecognized Tax Benefits
UnrecognizedTaxBenefits
2339000
CY2021Q4 us-gaap Unrecognized Tax Benefits
UnrecognizedTaxBenefits
1359000
CY2023 nktx Unrecognized Tax Benefits Increases Decreases Resulting From Prior Period Tax Positions
UnrecognizedTaxBenefitsIncreasesDecreasesResultingFromPriorPeriodTaxPositions
102000
CY2022 nktx Unrecognized Tax Benefits Increases Decreases Resulting From Prior Period Tax Positions
UnrecognizedTaxBenefitsIncreasesDecreasesResultingFromPriorPeriodTaxPositions
-43000
CY2023 us-gaap Unrecognized Tax Benefits Increases Resulting From Current Period Tax Positions
UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions
1297000
CY2022 us-gaap Unrecognized Tax Benefits Increases Resulting From Current Period Tax Positions
UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions
1023000
CY2023Q4 us-gaap Unrecognized Tax Benefits
UnrecognizedTaxBenefits
3738000
CY2022Q4 us-gaap Unrecognized Tax Benefits
UnrecognizedTaxBenefits
2339000
CY2023Q4 us-gaap Restructuring And Related Activities Initiation Date
RestructuringAndRelatedActivitiesInitiationDate
2023-10-16
CY2023Q4 us-gaap Restructuring And Related Cost Number Of Positions Eliminated
RestructuringAndRelatedCostNumberOfPositionsEliminated
18
CY2023Q4 us-gaap Restructuring And Related Cost Number Of Positions Eliminated Period Percent
RestructuringAndRelatedCostNumberOfPositionsEliminatedPeriodPercent
0.10
CY2023Q4 us-gaap Restructuring Costs
RestructuringCosts
1200000
CY2023 us-gaap Payments For Restructuring
PaymentsForRestructuring
800000
CY2023Q4 us-gaap Restructuring Reserve
RestructuringReserve
400000
CY2023Q4 ecd Rule10b51 Arr Adopted Flag
Rule10b51ArrAdoptedFlag
false
CY2023Q4 ecd Non Rule10b51 Arr Adopted Flag
NonRule10b51ArrAdoptedFlag
false
CY2023Q4 nktx Rule10 B51 Arr Modified Flag
Rule10B51ArrModifiedFlag
false
CY2023Q4 nktx Non Rule10 B51 Arr Modified Flag
NonRule10B51ArrModifiedFlag
false
CY2023Q4 ecd Rule10b51 Arr Trmntd Flag
Rule10b51ArrTrmntdFlag
false
CY2023Q4 ecd Non Rule10b51 Arr Trmntd Flag
NonRule10b51ArrTrmntdFlag
false

Files In Submission

Name View Source Status
0000950170-24-034735-index-headers.html Edgar Link pending
0000950170-24-034735-index.html Edgar Link pending
0000950170-24-034735.txt Edgar Link pending
0000950170-24-034735-xbrl.zip Edgar Link pending
Financial_Report.xlsx Edgar Link pending
img179161570_0.jpg Edgar Link pending
img184572170_0.jpg Edgar Link pending
img184572170_1.jpg Edgar Link pending
img184572170_2.jpg Edgar Link pending
img184572170_3.jpg Edgar Link pending
img184572170_4.jpg Edgar Link pending
img184572170_5.jpg Edgar Link pending
img184572170_6.jpg Edgar Link pending
img184572170_7.jpg Edgar Link pending
img184572170_8.jpg Edgar Link pending
img184572170_9.jpg Edgar Link pending
MetaLinks.json Edgar Link pending
nktx-20231231.htm Edgar Link pending
nktx-20231231.xsd Edgar Link pending
nktx-ex10_6d.htm Edgar Link pending
nktx-ex23_1.htm Edgar Link pending
nktx-ex31_1.htm Edgar Link pending
nktx-ex31_2.htm Edgar Link pending
nktx-ex32.htm Edgar Link pending
nktx-ex4_3.htm Edgar Link pending
nktx-ex97.htm Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
FilingSummary.xml Edgar Link unprocessable
nktx-20231231_htm.xml Edgar Link completed
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R35.htm Edgar Link pending
R36.htm Edgar Link pending
R37.htm Edgar Link pending
R38.htm Edgar Link pending
R39.htm Edgar Link pending
R4.htm Edgar Link pending
R40.htm Edgar Link pending
R41.htm Edgar Link pending
R42.htm Edgar Link pending
R43.htm Edgar Link pending
R44.htm Edgar Link pending
R45.htm Edgar Link pending
R46.htm Edgar Link pending
R47.htm Edgar Link pending
R48.htm Edgar Link pending
R49.htm Edgar Link pending
R5.htm Edgar Link pending
R50.htm Edgar Link pending
R51.htm Edgar Link pending
R52.htm Edgar Link pending
R53.htm Edgar Link pending
R54.htm Edgar Link pending
R55.htm Edgar Link pending
R56.htm Edgar Link pending
R57.htm Edgar Link pending
R58.htm Edgar Link pending
R59.htm Edgar Link pending
R6.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending